HRTIS — Herantis Pharma Oyj Balance Sheet
0.000.00%
Annual balance sheet for Herantis Pharma Oyj, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | FAS | FAS | FAS | FAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 7.42 | 5.99 | 6.49 | 2.13 | 2.6 |
| Net Total Receivables | 0.118 | 0.198 | 0.238 | 0.208 | 0.037 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 7.6 | 6.23 | 6.75 | 2.57 | 2.67 |
| Net Property, Plant And Equipment | 0 | 0 | — | — | — |
| Net Intangible Assets | |||||
| Total Assets | 7.76 | 6.23 | 6.75 | 2.57 | 2.67 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.61 | 1.9 | 1.99 | 0.634 | 0.912 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 8.9 | 6.29 | 2.02 | 2.81 | 4.36 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -1.14 | -0.06 | 4.73 | -0.243 | -1.69 |
| Total Liabilities & Shareholders' Equity | 7.76 | 6.23 | 6.75 | 2.57 | 2.67 |
| Total Common Shares Outstanding |